MENU
Aim higher

SwitchItOn

Novel genomic switches for 2nd generation in vivo models of human disease

New genomic switches will be developed which will allow to turn on/off multiple (trans)genes independently of each other in vivo. First prototypes of three inducible systems are available, E-Rex, Phlo, & RuX, which can regulate gene expression by adding erythromycin (Ery), phloretin (Phlo) or RU486 to the system. In order to bring these expression systems to the market, all three systems need optimization in terms of increasing tightness, inducibility, sensitivity and reversibility.
Ranking: 
21
Cut-off: 
7
Start date: 
01-11-2017
Project Duration: 
36months
Project costs: 
1 821 010.00€
Technological Area: 
Genetic Engineering
Market Area: 
Therapeutic services